Literature DB >> 17989974

Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam.

Mária Tóth, Sándor Drabant, Bálint Varga, Gyula Végso, Anna Cseh, Imre Szentpéteri, Imre Klebovich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17989974     DOI： 10.1007/s00228-007-0397-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  7 in total

1.  Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs.

Authors:  Toshiro Niwa; Toshifumi Shiraga; Ikuko Ishii; Akira Kagayama; Akira Takagi
Journal:  Biol Pharm Bull       Date:  2005-09       Impact factor: 2.233

2.  Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam.

Authors:  Sándor Drabant; Mária Tóth; Andrea Bereczki; Judit Bajnógel; Judit Tömlö; Imre Klebovich
Journal:  Eur J Clin Pharmacol       Date:  2006-06-22       Impact factor: 2.953

3.  [Effect of tofisopam on CYP3A4 enzyme activity on human recombinant 3A4 supersome].

Authors:  Mária Tóth; Judit Bajnógel; András Egyed; Sándor Drabant; Judit Tömlo; Imre Klebovich
Journal:  Acta Pharm Hung       Date:  2005

Review 4.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Extra-hepatic metabolism of midazolam.

Authors:  G R Park; A R Manara; S Dawling
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

6.  Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

Authors:  K E Thummel; D O'Shea; M F Paine; D D Shen; K L Kunze; J D Perkins; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1996-05       Impact factor: 6.875

Review 7.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447
  7 in total
  1 in total

1.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.